Business

Weight Loss Drug Trial Results

Updated 2026-09-30 14:40 UTC 1 source Neutral

Lilly’s new drug, when added to Zepbound, helped people lose up to 23% of their weight. However, the trial also revealed more side effects. The company is now testing an experimental amylin drug for similar benefits in managing diabetes.

Coverage timeline — 2 articles

MarketWatch

This is the big risk that stock investors should be watching as rising bond yields menace markets

While investors worry a spike in global bond yields will drag U.S. equities into correction territory, strategists at BofA Global Research say the real threat lies elsewhere.

2026-09-30 14:31 UTC

MarketWatch

Adding Lilly’s new drug to Zepbound helped people lose up to 23% of their weight. But there were more side effects.

The company is working on an experimental amylin drug to see if it can help people lose weight and manage their diabetes — much like a GLP-1.

2026-09-30 14:32 UTC